Cargando…

Serum calprotectin levels do not predict subsequent relapse in rheumatoid arthritis in remission: a post-hoc analysis of STRASS study

Detalles Bibliográficos
Autores principales:	Romand, Xavier, Clapasson, Margot, Chuong, Minh Vu, Paclet, Marie Hélène, Fautrel, Bruno, Baillet, Athan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410922/ https://www.ncbi.nlm.nih.gov/pubmed/37364929 http://dx.doi.org/10.1136/rmdopen-2023-003198

Ejemplares similares

Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial
por: Romand, Xavier, et al.
Publicado: (2023)

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
por: Sigaux, Johanna, et al.
Publicado: (2017)

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
por: Smith, Samantha Louise, et al.
Publicado: (2023)

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study
por: Jansen, Diahann T S L, et al.
Publicado: (2018)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry
por: Nourisson, Cynthia, et al.
Publicado: (2017)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
por: Tweehuysen, Lieke, et al.
Publicado: (2018)

Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis
por: Accortt, Neil A., et al.
Publicado: (2018)

Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment
por: Fautrel, B, et al.
Publicado: (2015)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis
por: Scott, I C, et al.
Publicado: (2016)

Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
por: Granger, Benjamin, et al.
Publicado: (2016)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
por: Aletaha, Daniel, et al.
Publicado: (2021)

Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
por: Smolen, Josef S, et al.
Publicado: (2021)

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
por: Akdemir, Gülşah, et al.
Publicado: (2018)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
por: Kubo, Satoshi, et al.
Publicado: (2023)

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
por: Fleischmann, Roy, et al.
Publicado: (2023)

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database
por: Seror, Raphaele, et al.
Publicado: (2022)

Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data
Publicado: (2018)

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
por: Emery, Paul, et al.
Publicado: (2020)

Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System
por: Gaujoux-Viala, Cécile, et al.
Publicado: (2023)

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
por: Chatzidionysiou, Katerina, et al.
Publicado: (2019)

ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)
por: Pope, Janet E, et al.
Publicado: (2018)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists
por: Hifinger, Monika, et al.
Publicado: (2017)

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022)

Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis
por: Boyapati, Anita, et al.
Publicado: (2020)

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight–joint Disease Activity Score, C-reactive protein level and patient global assessment
por: Felson, David, et al.
Publicado: (2021)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study
por: Calabrese, Leonard H., et al.
Publicado: (2020)

Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis
por: Lindqvist, Joakim, et al.
Publicado: (2023)

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
por: Lillegraven, Siri, et al.
Publicado: (2023)

Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe
por: Taylor, Peter C., et al.
Publicado: (2022)

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tph29igf91gab845vnvcq3sjtd